Single-Agent Chemotherapy

1987 ◽  
pp. 135-145 ◽  
Author(s):  
Donald P. Goldstein ◽  
Ross S. Berkowitz
Keyword(s):  
Single Agent ◽  
Single Agent Chemotherapy

scholarly journals Primary Nongestational Choriocarcinoma of the Ovary

2014 ◽  
Vol 4 (1) ◽  
pp. 56-59
Author(s):  
AMM Shariful Alam ◽  
Syeda Nurjahan Bhuiyan ◽  
Md Rashid Un Nabi
Keyword(s):  
Germ Cell ◽  
Combination Chemotherapy ◽  
Single Agent ◽  
Ovarian Pregnancy ◽  
Cell Neoplasm ◽  
Aggressive Tumor ◽  
Single Agent Chemotherapy ◽  
Disease Free ◽  
Worse Prognosis ◽  
Unmarried Girl

Pure primary ovarian choriocarcinoma is an extremely rare and aggressive tumor. It can be of gestational or nongestational in origin. The gestational type can arise from an ovarian pregnancy or can be of metastatic origin from uterine choriocarcinoma. The nongestational type is a very rare germ cell neoplasm. It is important to distinguish between two types of choriocarcinomas as nongestational origin is highly malignant and has worse prognosis than gestational type. But it is very difficult to differentiate by routine histological examination. Nongestational choriocarcinoma has been found to be resistant to single agent chemotherapy. It occurs usually around 13 years of age and is mainly confined to females under 20. Here we report a case of primary pure nongestational choriocarcinoma of the ovary in an unmarried girl of 14 years, diagnosed in 2001 and treated successfully with surgery and combination chemotherapy and remained disease-free till last reporting in September 2013. DOI: http://dx.doi.org/10.3329/jemc.v4i1.18070 J Enam Med Col 2014; 4(1): 56-59

scholarly journals Sequential dose-dense single agent chemotherapy for locally advanced breast cancer

2003 ◽  
Vol 11 (3) ◽  
pp. 149-149
Author(s):  
Svetislav Vrbic ◽  
Ivica Pejcic ◽  
Sladjana Filipovic ◽  
Stojan Radic
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Single Agent ◽  
Locally Advanced ◽  
Conservative Surgery ◽  
Advanced Breast ◽  
Dose Dense ◽  
Novel Concept ◽  
Single Agent Chemotherapy

Chemotherapy of breast cancer is still the area of intensive research. Based on mathematical model of tumor cell growth kinetics, articulated by Larry Norton, novel concept of chemotherapy in breast cancer was launched and it implies dose-densification of chemotherapy trough the use of sequential non cross-resistant single agents or regimens. The introduction of primary systemic chemotherapy (PST) improved the outcome of patients with locally advanced breast cancer (LABC). Simultaneous PST is the standard approach to patients with LABC nowadays. On the other hand, many studies using two most active cytotoxic drugs in primary breast cancer, anthracyclines and taxanes showed that sequential dose-dense single agent PST could be superior in terms of enhancing the rates of patients suitable for conservative surgery. In the light of this data, based on the results of the new clinical trials we will discuss merits and demerits of using sequential dose-dense single agent chemotherapy in LABC.

scholarly journals Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment

2018 ◽  
Vol 24 (23) ◽  
pp. 6040-6052 ◽  
Author(s):  
T. Leigh Spencer Noakes ◽  
Thomas S. Przybycien ◽  
Amanda Forwell ◽  
Connor Nicholls ◽  
Yu-Qing Zhou ◽  
...  
Keyword(s):  
Mouse Model ◽  
Brain Development ◽  
Childhood Leukemia ◽  
Heart Function ◽  
Single Agent ◽  
Leukemia Treatment ◽  
Single Agent Chemotherapy

Composite Prolymphocytoid and Hodgkin Transformation of Chronic Lymphocytic Leukemia

2000 ◽  
Vol 124 (6) ◽  
pp. 907-909 ◽  
Author(s):  
Maureen J. O'Sullivan ◽  
Zahid Kaleem ◽  
Michael J. Bolger ◽  
Paul E. Swanson ◽  
Mary M. Zutter
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hodgkin Lymphoma ◽  
Progressive Disease ◽  
Plasma Cells ◽  
Single Agent ◽  
Malignant Neoplasm ◽  
Lymphocytic Leukemia ◽  
Richter Syndrome ◽  
Classic Hodgkin Lymphoma ◽  
Single Agent Chemotherapy

Abstract The indolent course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is occasionally altered by transformation to a histologically distinct, rapidly progressive, and clinically unresponsive hematologic malignant neoplasm. We report a case of CLL that, after 3 years of slowly progressive disease and treatment with single-agent chemotherapy (fludarabine phosphate), underwent a composite prolymphocytoid and classic Hodgkin lymphoma transformation. The diagnosis of classic Hodgkin lymphoma was based on the presence of Reed-Sternberg cells with typical morphologic structure and immunophenotype (CD15+, CD30+, CD45−, CD20−) associated with the characteristic polymorphous inflammatory background consisting of numerous eosinophils, plasma cells, and reactive T lymphocytes. The remainder of the lymph node and the peripheral blood showed increased numbers of prolymphocytes admixed with typical small CLL cells. Recognition of such a transformation is of the utmost importance, since histologically similar Reed-Sternberg–like cells may be seen in Richter transformation. In contrast to prolymphocytoid transformation of CLL, Richter syndrome is rapidly fatal, with a median survival of 4 to 5 months. The patient pursued a clinical course similar to pure prolymphocytoid transformation and died with disease after 30 months following treatment with combination chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document